KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Non-Current Debt: 2018-2025

Historic Non-Current Debt for Castle Biosciences (CSTL) over the last 4 years, with Sep 2025 value amounting to $10.0 million.

  • Castle Biosciences' Non-Current Debt rose 0.34% to $10.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.0 million, marking a year-over-year increase of 0.34%. This contributed to the annual value of $9.7 million for FY2024, which is N/A change from last year.
  • Castle Biosciences' Non-Current Debt amounted to $10.0 million in Q3 2025, which was up 24.12% from $8.1 million recorded in Q2 2025.
  • Castle Biosciences' 5-year Non-Current Debt high stood at $10.0 million for Q3 2025, and its period low was $8.1 million during Q2 2025.
  • Over the past 2 years, Castle Biosciences' median Non-Current Debt value was $10.0 million (recorded in 2024), while the average stood at $9.5 million.
  • Over the last 5 years, Castle Biosciences' Non-Current Debt had its largest YoY gain of 0.34% in 2025, and its largest YoY loss of 19.10% in 2025.
  • Castle Biosciences' Non-Current Debt (Quarterly) stood at $9.7 million in 2024, then climbed by 0.34% to $10.0 million in 2025.
  • Its last three reported values are $10.0 million in Q3 2025, $8.1 million for Q2 2025, and $8.9 million during Q1 2025.